ArchiMed-backed NAMSA, a provider of full continuum development solutions, completed its acquisition of Syntactx, a CRO with expertise in complex interventional medical device and pharmaceutical trials across multiple therapeutic areas. Financial terms were not disclosed. "Not only are our values and cultures well-aligned, but both organizations have a strong commitment to enhancing patient healthcare by safely and judiciously helping clients deliver innovative, life-changing medical devices to the global marketplace," John Gorski, NAMSA President and CEO.